Overview

Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19

Status:
Not yet recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Convalescent plasma is a way to provide passive immunity to a person exposed to an infectious agent. It has been used as a therapeutic tool for emerging viral infections without specific treatment and with high morbidity and mortality, such as Influenza H1N1, H5N1, H7N9, Ebola, MERS, SARS-CoV1, and even SARS-Cov2, with satisfactory results regarding evolution clinic of patients treated and without significant adverse events reported. One of its main advantages of convalescent plasma is to generate a rapid immune response (even faster than a vaccine), against a pathogen that circulates in a specific geographic area, probably common for both donor and recipient.
Phase:
Phase 2
Details
Lead Sponsor:
National Blood Center Foundation, Hemolife
Collaborator:
Universidad de Antioquia